Why Is Everyone Talking About Gamida Cell Stock?
Gamida Cell (NASDAQ: GMDA) and its approach to attacking cancer with natural killer cells faded into the shadows shortly after the company's stock market debut in 2018. After years of languishing, clinical trial results presented during a virtual scientific conference recently propelled this under-the-radar stock 50% higher overnight.
Here's why scientists and investors are increasingly interested in Gamida Cell's novel cancer therapy candidates.
Image source: Getty Images.
Source Fool.com
